000020 — Dongwha Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Market Cap
KR₩174bn
Enterprise Value
KR₩259bn
Revenue
KR₩465bn

Annual income statement for Dongwha Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	272,075	293,018	340,426	361,109	464,875
Cost of Revenue
Gross Profit	138,666	149,347	180,990	190,416	214,258
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	248,962	270,732	313,989	342,825	451,866
Operating Profit	23,113	22,286	26,437	18,284	13,009
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	33,638	26,527	23,086	36,956	6,902
Provision for Income Taxes
Net Income After Taxes	28,715	19,583	21,591	28,237	2,146
Minority Interest
Net Income Before Extraordinary Items
Net Income	28,508	17,870	20,383	27,438	5,563
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	28,519	17,870	20,383	27,438	5,563
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	803	648	847	1,004	210
Dividends per Share